4Life Transfer Factor RioVida ®

4Life Transfer Factor RioVida ®

A Liquid Powerhouse
4Life Transfer Factor RioVida is the one-and-only juice beverage in the world that provides the benefits of 4Life Transfer Factor . RioVida is also infused with antioxidant fruit juices, such as açaí, pomegranate, blueberry, elderberry, and purple grape. Get your daily rush of vitality with RioVida!
Primary Benefit

•Promotes general wellness by supporting your body’s needs
What makes this product unique?
•Transfer factors are tiny messenger molecules that transfer Mother Nature’s natural response information from one entity to another, such as between a mother and her breastfeeding infant. •This is the first product to stabilize transfer factors in a liquid.

Product Testimonials

I’ve been taking 4Life Transfer Factor Cardio and 4Life Transfer Factor RioVida to help support the health of my cardiovascular system. I was especially interested in promoting a healthy inflammatory response. I am so grateful for the support I received from these products.
—Caroline L. 4Life Distributor, New Zealand

My husband and I both work full-time and have a young family as well. Our busy lives left us both bushed by the end of the day and we literally fell into bed each night. We’ve been drinking 4Life Transfer Factor RioVida for about six weeks now and we love it! We love the energy support we receive to accomplish the daily tasks of our hectic lives. I have also personally noticed wonderful antioxidant support for my joints as a result of drinking RioVida. As a former ballet dancer and skier this has been a great added bonus for me. We both can’t get enough of the taste of RioVida and have been raving about it to everybody that we meet. Thanks, 4Life!
—”—Bobby H. 4Life Distributor, Australia

4Life Transfer Factor RioVida is fantastic. I love the energy I have. I feel so good that I’m able to lift weights! This is truly the best product 4Life has ever made!

—Imran R. 4Life Distributor, Canada

A few weeks ago, I got my first order of 4Life Transfer Factor RioVida. My daughter and son-in-law wanted to try it out with their seven year-old son, my grandson. The next morning my daughter called to say that he woke up with lots of enthusiasm and a smile. He was excited to go to school. He had a great day in class followed by a two-hour baseball practice and he was still going strong.
—Linda B. 4Life Distributor, Ohio

My wife and I love 4Life Transfer Factor RioVida but what has impressed us even more has been our experiences with our daughter. She’s a vibrant, active, cheerful, and beautiful girl, and RioVida has promoted a wonderful level of overall health and vitality, including immune system support. RioVida is an excellent product for our children.
—Sergio R. 4Life Distributor Mexico


March 7, 2011 Posted by | 4LIFE, HEALTH, JANTUNG, KESIHATAN | , , , , , , , , , , , | Leave a comment

Tahniahhhh Winners4Life


Tahniah juga buat usahawan Melayu Winners4life yang telah mencapai anugerah ke dua tertinggi 4life G.I.D


October 20, 2010 Posted by | 4LIFE, BERAMAL SAMBIL DAPAT WANG(4LIFE), KESIHATAN, KEWANGAN, Uncategorized | , , , , , , , , , , , , , | Leave a comment


Sekiranya anda pentingkan kesihatan anda sekeluarga,sila lihat video ini dan tambahkan ilmu didada anda….

Berminat untuk menjadi pengedar 4life produk atau hanya ingin mencuba ??

Hubungi saya di 0163153132/0163143695 untuk maklumat lanjut.

September 28, 2010 Posted by | 4LIFE, BERAMAL SAMBIL DAPAT WANG(4LIFE), HEALTH, KESIHATAN, WANITA | , , , , , , , , , , , , , , , , , , | Leave a comment


Apakah itu Melamine ?

Melamine ialah bes organik yang terdiri daripada karbon,oksigen dan nitrogen. Bahan kimia ini kali pertama dihasilkan

oleh Justus von Liebig pada 1830 yang kemudiannya dihasilkan secara besar-besaran untuk kegunaan industri.

Seperti yang kita sedia maklum, melamine merupakan bahan yang digunakan untuk membuat pinggan mangkuk

melamine. Selain itu, melamine juga digunakan untuk menyelaputi permukaan plastik dan kayu.

Melamine mempunyai kandungan nitrogen yang tinggi.Oleh itu, dengan mencampurkan bahan kimia ini ke

dalam susu yang dicairkan akan mengaburi bacaan sebenar tahap protein pada susu tersebut. Penambahan

Melamine dalam makanan adalah menyalahi undang¬undang di bawah Akta Makanan 1983 dan

Peraturan¬Peraturan Makanan 1985.

Walaupun melamine sangat larut di dalam air dan mudah disingkarkan melalui urin, buah pinggang manusia tetap

mempunyai hadnya tersendiri. Akibatnya, pada dos melamine yang tinggi, ginjal tidak lagi mampu menyingkirkannya

dari tubuh badan manusia. Oleh itu, kepekatan melamine akan bertambah seterusnya membentuk kristal

yang turut dikenali sebagai batu karang.Pembentukkan batu karang ini akan bertambah saiz dari

semasa ke semasa yang akhirnya menyebabkan kegagalan ginjal yang serius.

Pada Mac 2007 yang lalu, satu kajian oleh pakar toksikologi,Perry Martos dari Universiti University of

Guelph mendapati ada satu lagi bahan kimia yang mendorong kepada pembentukan batu karang akibat

melamine iaitu cyanuric acid. Gabungan kedua-dua bahan kimia ini boleh menyebabkan pembentukan batu

karang yang sekaligus menyebabkan kegagalan ginjal.

Kesan melamine secara langsung mengakibatkan iritasi apabila terhidu dan bersentuhan dengan kulit atau mata.

Pengambilan melamine melalui makanan boleh mengakibatkan


kerosakan pada sistem pembiakan

•pembentukkan batu karang dalam ginjal dan

pundi kencing. Ini boleh mengakibatkan kegagalan ginjal terutamanya kepada bayi

Sebagai langkah proaktif ,semua pihak disarankan agar ibubapa dapat memantau gejala masalah buah pinggang seperti

bayi menangis tanpa sebab ketika kencing, kencing berdarah,dan tekanan darah tinggi pada bayi.



October 17, 2008 Posted by | artikel, buah pinggang, indonesia, KESIHATAN, malaysia | , , , , , , , , , , , , , | Leave a comment


Transfer factor (TF) is an extract of low molecular weight containing several lymphokine molecules with immunomodulating properties. It has been described for the first time by Lawrence in the early ‘50s. It seems capable of transferring antigen-specific information to T-lymphocytes, and it is present in the lymphocytes of mammals and birds. It has been widely used over the past forty years in the treatment of viral, parasitic, fungal infections and allergic disorders, as well as immunodeficiencies, neoplasias, viz. cancer of the lung and prostate. Encouraging clinical results have also been observed in patients suffering from candidiasis and tuberculosis.

It has been thought that the potential of this compound for answering the challenge of unknown pathogenic agents is considerable as is its preventative potential. Data have shown that antigen-specific TF administered before a viral infection can prevent the onset of the disease, TF acting as a preventative vaccine based on cell mediated immunity.

Its molecular structure has only partially been unravelled. It seems that to a small peptide (ca. 5000 DA) are attached 2-3 ribonucleotides. However, this lack of knowledge did not prevent its clinical use since it is possible to produce large quantities of specific transfer factor in tissue culture or in immunised animals.

The first observations postulating the existence and establishing the concept of transfer factor dates from the early 1950s when H.S. Lawrence showed that delayed type hypersensitivity (DTH) to a given antigen could be transferred from one individual to another via cell-free extracts obtained from the leucocytes of an immunised donor. He assumed that this adoptive transfer of immunity was due to a molecule which he named transfer factor and he surmised that its molecular weight was less than 12,000 Daltons, as it filters through a standard dialysis bag. Since that time, all transfer factor preparations for clinical and experimental studies have been obtained by disrupting lymphocytes, dialysing the lysates and using the dialysed material for in vitro tests or in vivo clinical or animal studies.

Over fifteen hundred reports have confirmed Lawrence’s original observations and established that the dialyzable extracts thus obtained are capable of transferring specific immune information in vitro to naïve lymphocytes or in vivo to patients or experimental animals. This information concerns only cell-mediated but not humoral immunity, no de novo antibody production has ever been elicited by transfer factor, although it has been reported that it may modulate normal antibody production triggered by conventional immunisation.

Since the early 70’s, transfer factor has been used more often than not successfully for the treatment of viral, parasitic, fungal infections, and also as an adjuvant treatment in autoimmune, allergic and malignant disorders. Its apparent success is of no surprise since cell-mediated immunity (CMI) plays a crucial role in the control of infectious, parasitic, and autoimmune diseases, as well as cancer.

Because the TF extract is usually obtained from the total lymphocyte population containing helper and suppressor lymphocytes, it acts as a modulator of the immune system. It boosts the immune defences when required, e.g. in infectious, malignant or genetically impaired immune disorders or it exerts a suppressing effect on a hyperactive immune system when its down-regulation is desirable, e.g. in allergic disorders.

The mechanism of action of TF remains largely unknown, its activity, in addition to the transfer of immune information, is manifested as a non-specific modulation of the immune response. It is known that the dialyzable extract containing the TF molecules also contains other low molecular weight lymphokines e.g. IMREG 1 and 2. Thus, its non-antigen-specific immunomodulating activity, which may also play a role in the regulation of humoral immunity, is due to molecules present in the dialysate, but distinct from those responsible for the transfer of antigen-specific information.

It seems that the total dialysate obtained from peripheral lymphocytes is a cocktail of molecules that provide immunoregulatory activity, in addition to the adoptive transfer of novel antigenic specificities to the immunological memory of the recipient. Hence the qualification of TF as an immunomodulator, i.e. a lymphokine with immunomodulatory activity mediating adoptive immunity, in contrast with so-called active (antibody induction by immunisation with the corresponding antigen) or passive (mediated by antibody injection) immunity.

Nonetheless, and notwithstanding encouraging clinical results, many drawbacks have impeded research in this field and fast advances in understanding the nature and mode of action of this intriguing biological entity.

Until 1974, the only source of transfer factor was pooled leucocytes from blood donors, which limited material supplies, whereas the biological potency and specific activity of the extract varied from one preparation to another. Indeed, the precise antigenic specificity of the various batches of material used was practically unknown, but presumably large, since each batch reflected the collective immune experience of several individuals. For this reason, these preparations were improperly called “non-specific”, indicating multiple but unknown specificities.

Thus, despite several encouraging reports in the early 1970s, the clinical use of transfer factor was curtailed by the dearth of material with standardised and consistent activity. Similarly, biochemical studies were virtually impossible for lack of sufficient raw material for purification. In 1974, Viza and co-workers reported that TF with known specificities could be replicated in tissue culture, using a lymphoblastoid cell line. In the late 1970s, the same group and other investigators presented evidence that specific TF obtained from mammals after immunisation with a given antigen was also active in humans.

Nevertheless, in spite of the resolution of the supply problem, the controversy relating to this molecule was to grow. There are several reasons for this, and they pertain mainly to its unusual characteristics.

Nearly fifty years after Lawrence’s original observations, transfer factor remains an elusive and controversial entity, despite enormous laboratory efforts and several clinical studies with encouraging and sometimes spectacular results. Biochemical studies have already produced evidence that the molecule responsible for the transfer of the antigenic specificity is a small peptide with a molecular weight of approximately 5000 DA, and it has been suggested that two to three ribonucleotides are attached to the peptide. Unfortunately, attempts at sequencing the peptide have failed, because of the presence of a blocked amino terminus.

The transfer of antigen-specific CMI information by this extract is thought provoking, for it apparently contravenes essential tenets of immunology and molecular biology. However, since the experimental evidence supporting the antigen-specific transfer is uncontested, various hypotheses for understanding its mechanism have been proposed, but so far none has proven totally acceptable.

The specificity issue thus remains one of the essential problems. TF dialysates contain non-specific immunoregulatory molecules which can usually enhance and, in certain cases, down-regulate CMI. Two such molecules named IMREG I and IMREG II were identified by Gottlieb and his co-workers. Nevertheless, such moieties could play a role in enhancing a weak response to a ubiquitous antigen and thus provide false evidence of specific transfer. Studies undertaken with such rare antigens as coccidioidin or keyhole limpet haemocyanin (KLH) preclude non-specific enhancement of “lapsed” immunological memory. Several human and animal studies have established that TF is capable of transferring CMI to rare antigens that the recipient is unlikely to have encountered by chance.

The overall picture became more complex when two types of antigen-specific activity were described within the dialysates: a) inducer or helper activity, which is the activity of the conventional transfer factor and b) anti-transfer factor or suppressor activity. The distinctive properties of the two entities are as follows: transfer factor binds to its related antigen, suppressor factor binds to the related antibody (IgG); inducer factor is absorbed by T suppressor cells and macrophages, whereas suppressor factor is absorbed by T-helper cells and macrophages; inducer factor derives from T-helper cells, suppressor factor from T-suppressor cells.

Be that as it may, TF’s characteristics (low molecular weight, undefined chemical structure, unconventional mode of action, protein-like nature but resistant to most proteolytic enzymes) together with its biological properties (non-species specificity, transfer of antigen-specific information) have generated more opponents than supporters. And the frustration resulting from unsuccessful attempts to solve this multi-faceted riddle, especially the failure so far to unravel the molecular structure, apparently due to a blocked amino terminus of the peptide forbidding its sequence by conventional methods, has led scientists to doubt its very existence.

Despite promising results and hundreds of publications, failure to explain TF’s mechanism of action and define its molecular structure aroused doubts about its very existence. And even though recent work by Kirkpatrick has partially determined an amino-acid sequence (LLYAQDLEDN), thus giving some biochemical reality to the elusive moiety, no further publication has confirmed and complemented these data since.

Moreover, the pharmaceutical industry did not pay sufficient attention to this moiety because of the prohibitive costs of bringing a new medicine onto the market and the lack of patent protection (the impossibility of filing patents after decades of published academic work). In addition, the difficulties involved in production made commercialisation unviable. And a compound producing such astounding results as those described in the scientific literature, and which has not been on the market for so many years, gradually begins to lose its credibility. As for the commercial preparations obtained from colostrums and today sold via the internet, they definitely decrease the credibility of the product. Their acclaimed effects have never been tested or confirmed independently, neither in vitro nor in vivo, and the alleged clinical improvements cannot thus be differentiated from a placebo effect.

Even if some clinical reports of the ‘70s are subject to justified criticism, hundreds of studies have established the efficacy of transfer factor in treating several pathologies. Its lack of toxicity and the absence of side effects made the use of this extract appealing. Moreover, despite current scepticism, no publication has ever rejected reported clinical claims. An impressive number of clinical studies have demonstrated the efficacy of transfer factor in treating and even preventing viral infections. For instance, Steele and co-workers were able to protect leukaemic children receiving chemotherapy from varicella zoster virus infections using varicella-zoster-specific transfer factor. In the early 1980s, Viza and Dwyer described significant improvement obtained by the use of herpes-simplex-virus-specific transfer factor in treating patients suffering from recurrent genital and/or labial herpes. The clinical observations were later corroborated by experiments in a mouse model.

Other clinical studies have shown that specific transfer factor may produce a spectacular improvement in acute cytomegalovirus (CMV) infections. Moreover, in Africa, children suffering from Burkitt’s lymphoma (a tumour caused by EBV) treated over a long period with EBV-specific TF showed a significant decrease in the rate of relapses. Other viral infections e.g. hepatitis B respond equally well to specific TF.

Transfer factor treatment has proven to be helpful in several neoplasias. One should cite the pioneering work of Fudenberg and that of Pizza. Osteosarcoma, melanoma, breast, lung, prostate and kidney cancer patients have benefited from TF therapy.

Parasitic infections also respond to TF therapy as the data of Sharma, confirmed by Delgado, in treating cutaneous leishmaniasis suggest. Other parasitic diseases known to respond effectively to TF are schistosomiasis and cryptosporidiosis, and several reports cite positive results obtained in treating patients with mycobacterial infections such as lepromatus leprosy, mycobacterium fortuitum pneumonia refractory to antibiotic therapy and tuberculosis. Chronic mucocutaneous candidiasis, an immunodeficiency characterized by chronically relapsing Candida albicans infections also responds well to TF treatment.




Ablashi DV, Levine PH, De Vinci C, Whitman JE Jr, Pizza G, Viza D: Use of anti HHV-6 transfer factor for the treatment of two patients with Chronic Fatigue Syndrome (CFS). Two case reports. Biotherapy 1996; 9: 81-86.

Bilello P, Fishman M, Koch G: Evidence that immune RNA is messenger RNA. Cell Immunol 1976; 23: 309.

Boucheix C, Phillips J, Pizza G, Sartorio C, Viza D: Activity of animal transfer factor in man. Lancet 1977; i: 189-99.

Burger DR, Vandenbark AA, Dunnic W, Kraybill WG, Vetto RM: Properties of human transfer factor from KLH-immunized donors: Dissociation of dermal transfer and proliferation augmenting activities. J Reticuloendothel Soc 1976; 24: 385-402.

Chang Y, Cesarman E, Pessin MS et al.: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994; 266: 1865-1869.

Delgado O, Romano EL, Belfort E, Pifano F, Scorza JV, Rojas Z: Dialyzable leukocyte extract therapy in immunodepressed patients with cutaneous leishmaniasis. Clin Immunol Immunopathol 1981; 19: 351-358.

Dwyer JM: The use of antigen-specific transfer factor in the management of infections with herpes viruses. In: C.H. Kirkpatrick et al. (eds.) Immunobiology of Transfer Factor. Academic Press, New York 1983: 233-243.

Fernandez-Ortega C, Dubed M, Ruibal O, Vilarrubia OL, Menendez de San Pedro JC, Navea L, Ojeda M, Arana MJ: Inhibition of in vitro HIV infection by dialysable leucocyte extracts. Biotherapy 1996; 9: 33-40.

Fudenberg HH, Fudenberg HL: Transfer factor: Past, present and future. In E. Jucker (ed.): Annual Review of Pharmacology and Toxicology. Birkhäuser Verlag, Basel, Switzerland 1989: 475-516.

Fudenberg HH, Levin AS, Spitler LE, Wybran J, Byers V: The therapeutic uses of transfer factor. Hosp Pract 1974; 9: 95-104.

Fujisawa T, Yamaguchi Y: Postoperative immunostimulation after complete resection improves survival of patients with stage 1 nonsmall cell lung carcinoma. Cancer 1996; 78: 1892-1898.

Galbraith GMP, Fudenberg HH: Transfer factor. In: J. Stone (ed.) : Dermatologic Immunology and Allergy. Mosby, St. Louis, Mo 1985: 889-98.

Gottlieb AA, Sizemore RC, Gottlieb MS, Kern CH: Rationale and clinical results of using leucocyte-derived immunosupportive therapies in HIV disease. Biotherapy 1996; 9: 27-31.

Griscelli C, Revillard JP, Betuel H, Herzog C, Touraine JL: Transfer factor therapy in immunodeficiencies. Biomedicine 1973; 18: 220-227.

Hastings RC, Morales MJ, Shannon EJ, Jacobson RR: Preliminary results in the safety and efficacy of transfer factor in leprosy. In: M.S. Asher, A.A. Gottlieb, C.H. Kirkpatrick (eds.): Transfer Factor: Basic Properties and Clinical Applications. Academic Press, New York 1976: 465-76.

Kirkpatrick C.H, Transfer Factors: Identification of Conserved Sequences in Transfer Factor Molecules. Mol Med 2000; 6(4): 332-341. Kirkpatrick CH, Greenberg LE: Treatment of chronic mucocutaneaous candidiasis with transfer factor. In: A. Khan, C.H. Kirkpatrick, N.O. Hill (eds.): Immune Regulators in Transfer Factor. Academic Press, New York 1979: 547-62.

Lawrence HS, Borkowsky W: Transfer Factor – Current status and future prospects. Biotherapy 1996; 9: 1-5.

Lawrence HS: The transfer in humans of delayed skin sensitivity to streptococci M substance and to tuberculin with disrupted leukocytes. J Clin Inv 1955; 34: 219-32.

Lesser PG, Margarido L, Bolda W, Sartori SG, Hares WA, Freire CA, Fleury R, Montenegro MR, Leser W, Naspitz CK: Cell-mediated immunity in patients with Virchowian Hanseniasis before and after treatment with transfer factor. Hansenol Int J 1980; 5(1); 3-27-34.

Levin AS, Byers VS, Fudenberg HH et al.: Osteogenic sarcoma: Immunologic parameters before and during immunotherapy with tumor specific transfer factor. J Clin Invest 1975; 55: 487-499.

Levin AS, Spitler LE, Stites DP, Fudenberg HH: Wiskott-Aldrich syndrome, a genetically determined cellular immunologic deficiency: clinical and laboratory response to therapy with transfer factor. PNAS 1970; 67: 821.

Masi M, De Vinci C, Baricordi OR: Transfer factor in chronic mucocutaneaous candidiasis. Biotherapy 1996; 9: 97-103.

McMeeking A, Borkowski W, Klesius PH, Bonk S, Holzman RS, Lawrence HS: A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS. J Infec Dis 1990; 161: 108-12. Meduri R, Campos E, Scorolli L, De Vinci C, Pizza G, Viza D: Efficacy of transfer factor in treating patients with recurrent ocular herpes infections. Biotherapy 1996; 9: 61-66.

Metcalf JF, John JF Jr, Wilson GB, Fudenberg HH, Harley RA: Mycobacterium-fortuitum pulmonary infection associated with an antigen-selective defect in cellular immunity. Am J Med 1981; 71: 485-491.

Neequaye J, Viza D, Pizza G, Levine PH, De Vinci C, Ablashi DV, Biggar RJ, Nkrumah F: Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt’s lymphoma. Anticanc R 1990; 10: 1183-1187.

Nkrumah F, Pizza G, Viza D, Phillips J, De Vinci C, Levine P: Regression of progressive lymphadenopathy in a young child with acute CMV infection following the administration of transfer factor with specific anti-CMV activity. Lymphok Res 1985; 4: 237-241.

Pilotti V, Mastrorilli M, Pizza G, DeVinci C, Busutti L, Palareti A, Gozetti G, Cavallari A: Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Biotherapy 1996; 9: 117-121.

Pizza G, Chiodo F, Colangeli V, Gritti F, Raise E, Fudenberg HH, De Vinci C, Viza D: Preliminary observations using HIV-specific transfer factor in AIDS. Biotherapy 1996; 9: 41-47.

Pizza G, De Vinci C, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Palareti A, Zucchelli P, Fornarola V, Viza D: A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer. Biotherapy 1996; 9: 123-132.

Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola V, Baricordi R: Orally administered HSV-specific transfer factor (transfer factor) prevents genital or labial herpes relapses. Biotherapy 1996; 9: 67-72.

Pizza G, Viza D, Roda A, Aldini R, Roda E, Barbara L: Transfer factor for the treatment of chronic active hepatitis. N Eng J Med 1979; 300: 1332.

Prasad U, bin Jalaludin MA, Rajadurai P, Pizza G, De Vinci C, Viza D, Levine PH: Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: A pilot study. Biotherapy 1996; 9: 109-115.

Rappaport FT, Lawrence HS, Millar JW, Pappagianis D, Smith CE: Transfer of delayed hypersensitivity to coccidioidin in man. J Immunol 1960; 84: 358-67.

Sharma MK, Anaraki F, Ala F: Preliminary results of transfer factor therapy of persistent cutaneous leishmania infection. Clin Immunol Immunopathol 1979; 12: 183-190.

Spitler LE, Levin AS, Stites DP, Fudenberg HH, Pirofsky B, August CS, Stiehm ER, Hitzig WH, Gatti RA: The Wiskott-Aldrich syndrome. Results of transfer factor therapy. J Clin Invest 1972; 51: 3216-24.

Steele WR, Myers MG, Vincent MM: Transfer factor for the prevention of varicella zoster infection in childhood leukaemia. N Eng J Med 1980; 303: 355-59.

Steele WR: Transfer factor and cellular reactivity to varicella zoster antigen in childhood leukaemia. Cell Immun 1980; 50: 202-89.

Vich JM, Viza D: Specific suppressor dialysates from mice. In: C.H. Kirkpatrick, D.R. Burger, H.S. Lawrence (eds.): Immunobiology of Transfer Factor. Academic Press, New York 1983: 197-202.

Vich JM, Garcia JV, Engel P, Garcia PA: Transfer to man of sensitization to Keyhole Limpet Haemocyanin by mouse transfer factor. Lancet 1978; i: 265.

Viza D, Goust JM, Moulias R, Trejdosiewicz LK, Collard A, Müllet-Bérat N: In vitro production of transfer factor by lymphoblastoid cell lines. Transplant 1975; VII (suppl. 1): 329-333.

Viza D, Lefesvre A, Patrasco M, Phillips J et al.: A preliminary report on three AIDS patients treated with anti-HIV specific transfer factor. J Exp Path 1987; 3: 653-659.

Viza D, Vich JM, Minarro A, Ablashi DV, Salahuddin SZ: Soluble extracts from a lymphoblastoid cell line modulate SAIDS evolution. J Virol Met 1988; 21: 241-253.

Viza D, Vich JM, Phillips J, Rosenfeld F, Davies DAL: Specific transfer factor protects mice against lethal challenge with herpes simplex virus. Cell Immun 1986; 100: 555-562.

Viza D, Vich JM, Phillips J, Rosenfeld F: Orally administered specific transfer factor for the treatment of herpes infections. Lymphok Res 1985; 4: 27-30.

Wilson GB, Metcalf JF Jr, Fudenberg HH: Treatment of mycobacterium-fortuitum pulmonary infection with “transfer factor” (TF): New methodology for evaluating TF potency and predicting clinical response. Clin Immunol Immunopathol 1982; 23: 478-483.



October 8, 2008 Posted by | 4LIFE, artikel, BARAH, indonesia, JANTUNG, kanser, KESIHATAN, malaysia | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment



October 7, 2008 Posted by | 4LIFE, artikel, BARAH, indonesia, JANTUNG, kanser, KESIHATAN, malaysia | , , , , , , , , , , , | Leave a comment

Transfer Factor knowledge.(ILMU TRANSFER FACTOR 4LIFE)




September 21, 2008 Posted by | 4LIFE, artikel, KESIHATAN, malaysia | , , , , , , , | Leave a comment

Kolestrol rendah meningkatkan peluang kanser??

Low Cholesterol Levels Increases Cancer Risk- American College of Cardiology

For years, I’ve been telling my patients that the medical establishment’s obsession with lowering cholesterol to prevent heart disease is causing more harm than good.

If your doctor continues to get you worried about your high cholesterol levels, here’s a bit of news for you…

In fact, your high cholesterol may be protecting you from cancer.

Today, I’ll explain the truth behind the myth of cholesterol, and show you how to achieve heart health naturally.

A new study published in the Journal of the American College of Cardiology revealed that driving down cholesterol levels actually increases the risk of cancer.

Researchers at the Tufts University School of Medicine found that among people taking “statin” drugs – like Lipitor and Zocor – there was a higher rate of cancer. Although the link between the drugs and cancer wasn’t clear, there was no doubt that drastically low cholesterol levels correlated to cancer risk.

The big drug makers continue to sell the notion that the best way to fight heart disease is to lower LDL levels, the so-called “bad” cholesterol.

Yet 75 percent of people who suffer heart attacks have normal cholesterol levels.

It makes sense that low cholesterol levels are linked to cancer because cholesterol is one of your body’s basic building blocks. You need it to produce testosterone, to build and repair cell membranes, and to preserve your nerve cells through the formation of the protective “sheaths” that cover them.

Starving your body of this critical substance will lead to other health problems. We already know that extremely low cholesterol levels result in muscle weakness, fatigue, depression, decreased sex drive, and “brain fog.” This new research shows that there may be even more deadly consequences.

What really matters is not low “bad” cholesterol, but high levels of HDL, the so-called “good” cholesterol. As long as you have a high HDL count – 75 to 80, for example – it doesn’t matter whether your total cholesterol is 150 or 350. A high HDL will always keep your risk of heart disease extremely low.

So why haven’t you heard this already? It may be because there’s no drug that effectively raises good cholesterol levels. You can only effectively do it naturally.

Consume natural fats. Avoid processed or fast foods containing “trans” fats – these man-made substances were never meant for consumption, and your body doesn’t know what to do with them. They wind up clogging your arteries and putting you on the fast track to heart disease.

Instead, get your fat from free-range or grass-fed animals, eggs, nuts, and unprocessed vegetable oils. These are some of the healthiest foods you can eat. (As with all foods, look for organic or minimally processed options whenever possible.)

The health benefit of these natural fats comes from their balance of Omega-3 and Omega-6 fatty acids. Your body needs both but, as with cholesterol, they have to be in balance. Omega-3s are great for your heart. They’ve been shown to prevent irregular heartbeat, reduce clogging of the arteries, lower blood pressure, and decrease inflammation in body tissues.
If you stick to eating natural fats, you’ll automatically get the right ratio of Omega-6 and Omega-3, which is about 2:1. As an added bonus, you’ll automatically raise your “good” cholesterol levels and you’ll reduce your risk of cancer.

To Your Good Health,

Al Sears, MD

August 25, 2008 Posted by | 4LIFE, artikel, BARAH, indonesia, JANTUNG, kanser, KESIHATAN, KEWANGAN, malaysia | , , , , , , , , , , , , , , , , , , , | Leave a comment


August 20, 2008 Posted by | 4LIFE, artikel, BARAH, kanser, KESIHATAN, KEWANGAN, malaysia | , , , , , , , , , | Leave a comment

Produk kecantikan 4life.Transfer Factor™ énummi™ SET


Transfer Factor enummi (8.5 oz bottle)

RM86.00 (12 LP)

ITEM # 130025003

enummi Lite Body Lotion (8.5 oz)

RM80.00 (12 LP)

ITEM # 130025023

enummi Gentle Facial Cleanser (4 oz)

RM62.00 (8 LP)

ITEM # 130025025

enummi Toner (4 oz)

RM80.00 (12 LP)

ITEM # 130025027

enummi Protective Day Moisturizer (1.7 oz)

RM138.00 (25 LP)

ITEM # 130025029

enummi Night Recovery Cream (1 oz)

RM162.00 (30 LP)

ITEM # 130025031

enummi Face System (set of 4)

RM414.00 (75 LP)

ITEM # 130025033

Healthy skin takes the same care and nourishment you give the rest of your body. 4Life Transfer Factor énummi helps provide immune support for the largest organ of your body, your skin, and delivers essential moisture to support the healthy tone and texture of skin. This blend of herbs, protective antioxidants, and 4Life Transfer Factor E-XF™ will help the skin maintain its resiliency. Perfect for every “body,” énummi’s formula is free of potentially harmful preservatives and additives. Use 4Life Transfer Factor énummi every day to look and feel healthy all over.

Primary Benefits

· Helps topically support the healthy function of your immune system with 4Life’s patented Transfer Factor E-XF blend
· Supports healthy skin with extracts of the Moringa plant, which contains a complex range of vitamins, minerals, and amino acids
· Provides protective antioxidant support for younger, healthier-looking skin
· Promotes soft, smooth skin with Aloe Vera and Shea butter

What makes this product unique?

Transfer factors are tiny messenger molecules that transfer Mother Nature’s natural response information from one entity to another, such as between a mother and her breastfeeding infant.
· The extraction processes for transfer factors from colostrum and egg sources are protected by 6,468,534 (egg yolks) and 6,866,868 (exclusive manufacturing techniques), with other patents pending.
· 4Life Transfer Factor products are featured in the Physicians’ Desk Reference: For Nonprescription Drugs and Dietary Supplements, the standard supplement guide found in physician offices, hospitals, and pharmacies in the United States.

Complementary Products

4Life Transfer Factor RioVida™
4Life Transfer Factor RenewAll™


Water, Aloe Vera Leaf Extract, Hybrid Safflower Seed Oil, Glycerin, Sunflower Oil, Glyceryl Stearate, Caprylic/Capric/ Myristic/Stearic Triglyceride, Shea Butter Fruit, Sandalwood Extract, Amur Corktree Bark Extract, Barley Extract, Cetyl Alcohol, Stearic Acid, Sodium Stearoyl Lactylate, Moringa Pterygosperma Seed Extract, Phenoxyethanol, Caprylyl Glycol, Sorbic Acid, Transfer Factor E-XF (a patented concentrate of transfer factors and other natural components from cow colostrum and egg yolk), White Tea Leaf Extract, Retinyl Palmitate, Ascorbyl Palmitate, Tocopheryl Acetate, Phospholipids, Dimethicone, Carbomer, Disodium EDTA, Sodium PCA, Fragrance, Allantoin, Glyceryl Stearate, PEG-100 Stearate, Cyclomethicone, Triethanolamine..

enummi Toothpaste (4 oz tube)

4Life enummi Toothpaste offers the immune benefits of 4Life Transfer Factor E-XF™ and other ingredients, including Coenzyme Q-10 and lactoferrin, to promote healthy teeth and gums.

enummi Gentle Facial Cleanser

(4 oz)

Scrub up with our Gentle Facial Cleanser, formulated with the finest in herbal extracts, natural emollients, vitamins, and antioxidants to wash away impurities, without stripping vital moisture from your face. Apply this light, foaming cleanser both morning and night for fresh, clean skin that’s ready for whatever life throws your way.

enummi Toner

(4 oz)

Mist away the day with Refreshing Toner. Infused with vitamins, antioxidants, and other plant emollients, it neutralizes surface impurities and brings needed moisture to your face. Add the immune support of Transfer Factor E-XF™ and the result is smoother, fresher, and brighter skin that’s primed for moisturizing—any time of the day!

enummi Protective Day Moisturizer (1.7 oz)

Your skin has a lot to deal with, so it needs powerful protection—our Protective Day Moisturizer, backed by SPF 15 to guard against both UVA and UVB rays. Light and natural, it blends together vitamins, antioxidants, and other nutrients to help promote soft, healthy, and younger-looking skin. And if all this weren’t enough, Transfer Factor E-XF™ provides key support for the immune function of skin cells.

eEummi Night Recovery Cream

(1 oz)

Wake up to healthier, refreshed skin! Night Recovery Cream helps your face unwind from daily wear and tear with aloe vera and Transfer Factor E-XF™ to support the health of your skin. Vitamins A and E and moisturizing agents balance and rejuvenate; antioxidants provide anti-aging benefits; and hydrating nutrients give thirsty skin a youthful appearance.

enummi Intensive Body Lotion

(8.5 oz)

You exercise to get your heart pumping. You eat plenty of fiber to keep your digestive system moving. What are you doing to keep your skin glowing?


August 2, 2008 Posted by | 4LIFE, body losyen, gadis, HEALTH, kecantikan, KESIHATAN, KEWANGAN, kulit, kulit sensitif, malaysia, PEREMPUAN, produk kulit, produk penjagaan kulit, sakit kulit, WANITA | , , , , , , , , , , , , , , , , , , , , | Leave a comment